KR20180113540A - 혈액암 및 고형 종양의 치료를 위한 idh2 저해제 - Google Patents

혈액암 및 고형 종양의 치료를 위한 idh2 저해제 Download PDF

Info

Publication number
KR20180113540A
KR20180113540A KR1020187024384A KR20187024384A KR20180113540A KR 20180113540 A KR20180113540 A KR 20180113540A KR 1020187024384 A KR1020187024384 A KR 1020187024384A KR 20187024384 A KR20187024384 A KR 20187024384A KR 20180113540 A KR20180113540 A KR 20180113540A
Authority
KR
South Korea
Prior art keywords
compound
idh2
flt3
mutant allele
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187024384A
Other languages
English (en)
Korean (ko)
Inventor
마이클 아마탄젤로
샤오란 휴
안잔 타쿠르타
성 은 최
빈 우
Original Assignee
셀진 코포레이션
아지오스 파마슈티컬스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀진 코포레이션, 아지오스 파마슈티컬스 아이엔씨. filed Critical 셀진 코포레이션
Publication of KR20180113540A publication Critical patent/KR20180113540A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020187024384A 2016-02-26 2016-12-02 혈액암 및 고형 종양의 치료를 위한 idh2 저해제 Ceased KR20180113540A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662300673P 2016-02-26 2016-02-26
US62/300,673 2016-02-26
PCT/US2016/064615 WO2017146794A1 (en) 2016-02-26 2016-12-02 Idh2 inhibitors for the treatment of haematological maligancies and solid tumours

Publications (1)

Publication Number Publication Date
KR20180113540A true KR20180113540A (ko) 2018-10-16

Family

ID=57610404

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187024384A Ceased KR20180113540A (ko) 2016-02-26 2016-12-02 혈액암 및 고형 종양의 치료를 위한 idh2 저해제
KR1020187027740A Ceased KR20180114202A (ko) 2016-02-26 2016-12-02 혈액 악성종양 및 고형 종양의 치료를 위한 idh1 억제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187027740A Ceased KR20180114202A (ko) 2016-02-26 2016-12-02 혈액 악성종양 및 고형 종양의 치료를 위한 idh1 억제제

Country Status (12)

Country Link
US (3) US10137130B2 (enExample)
EP (2) EP3419593B1 (enExample)
JP (3) JP6856657B2 (enExample)
KR (2) KR20180113540A (enExample)
CN (1) CN109069410B (enExample)
AU (2) AU2016393869B2 (enExample)
CA (2) CA3015757A1 (enExample)
ES (1) ES2912909T3 (enExample)
IL (2) IL261333B (enExample)
MA (1) MA43640A (enExample)
MX (3) MX390396B (enExample)
WO (2) WO2017146795A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CA2942072C (en) 2014-03-14 2022-07-26 Agios Pharmaceuticals, Inc. Pharmaceutical compositions and use of (s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-( 4-cyanopyridin-2-yl)-n-( 5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
PT3733662T (pt) 2014-09-19 2023-08-18 Forma Therapeutics Inc Derivados piridin-2(1h)-ona-quinolinona como inibidores de isocitrato desidrogenase mutante
US9771349B2 (en) 2014-09-19 2017-09-26 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
ES2768694T3 (es) 2014-09-19 2020-06-23 Forma Therapeutics Inc Composiciones de quinolinona pirimidinas como inhibidores de isocitrato dehidrogenasa mutante
EP3194375B1 (en) 2014-09-19 2018-11-21 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016053850A1 (en) 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR102628370B1 (ko) 2015-02-04 2024-01-24 르 라보레또레 쎄르비에르 치료적 활성 화합물 및 이들의 사용 방법
US9624216B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
US10294206B2 (en) 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
MA71411A (fr) 2015-10-15 2025-04-30 Les Laboratoires Servier Polythérapie pour le traitement de tumeurs malignes
SG10201912869WA (en) 2015-10-15 2020-02-27 Celgene Corp Combination therapy for treating malignancies
DK3362066T3 (da) 2015-10-15 2021-11-22 Les Laboratoires Servier Sas Kombinationsterapi til behandling af maligniteter
SG10201912886XA (en) 2015-10-15 2020-02-27 Agios Pharmaceuticals Inc Combination therapy for treating malignancies
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
EP3493809B1 (en) * 2016-08-03 2023-08-23 Celgene Corporation Enasidenib for treatment of myelodysplastic syndrome
CN109715143A (zh) 2016-09-07 2019-05-03 细胞基因公司 片剂组合物
ES2968376T3 (es) 2017-05-05 2024-05-09 Memorial Sloan Kettering Cancer Center Métodos de tratamiento de neoplasia mieloproliferativa
US11709164B2 (en) 2017-10-26 2023-07-25 National University Of Singapore Approach for universal monitoring of minimal residual disease in acute myeloid leukemia
WO2019109095A1 (en) * 2017-12-01 2019-06-06 Beth Israel Deaconess Medical Center, Inc. Arsenic trioxide and retinoic acid compounds for treatment of idh2-associated disorders
JP2021512166A (ja) 2018-01-30 2021-05-13 フォグホーン セラピューティクス インコーポレイテッドＦｏｇｈｏｒｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 化合物及びその使用
JP7523351B2 (ja) 2018-01-31 2024-07-26 デシフェラ・ファーマシューティカルズ，エルエルシー 肥満細胞症の治療のための併用療法
JP2021512105A (ja) 2018-01-31 2021-05-13 デシフェラ・ファーマシューティカルズ，エルエルシー 消化管間質腫瘍の治療のための併用療法
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US10532047B2 (en) 2018-05-16 2020-01-14 Forma Therapeutics, Inc. Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
EP3720442B1 (en) 2018-05-16 2022-12-28 Forma Therapeutics, Inc. Inhibiting mutant idh-1
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CA3103498A1 (en) * 2018-07-06 2020-01-09 Agios Pharmaceuticals, Inc. Ivosidenib forms and pharmaceutical compositions
US20210299233A1 (en) * 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
WO2020090968A1 (ja) * 2018-10-31 2020-05-07 富士フイルム株式会社 抗腫瘍剤を含む造粒物
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020117868A1 (en) * 2018-12-03 2020-06-11 Beth Israel-Deaconess Medical Center, Inc. Arsenic compounds and retinoic acid compounds for treatment of idh-associated disorders
WO2020117867A1 (en) * 2018-12-03 2020-06-11 Beth Israel-Deaconess Medical Center, Inc. Darinaparsin and retinoic acid compounds for treatment of idh-associated disorders
KR102035479B1 (ko) * 2019-04-12 2019-10-23 한국지질자원연구원 점토광물 복합체를 포함하는 방출성이 제어된 경구투여용 조성물
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
EP4041922A4 (en) 2019-10-07 2023-11-01 University Hospitals Cleveland Medical Center METHOD FOR TREATING WILD-TYPE ISOCITRATE DEHYDROGENASE-1 CANCER
CN112773797A (zh) * 2019-11-11 2021-05-11 江苏恒瑞医药股份有限公司 一种吡咯并六元杂环化合物在制备治疗flt3突变的肿瘤的药物中的用途
JP2023503842A (ja) * 2019-11-14 2023-02-01 セルジーン コーポレーション がんを処置するための小児用製剤
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
NZ789199A (en) 2019-12-30 2025-07-25 Deciphera Pharmaceuticals Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
JP7561195B2 (ja) 2020-01-29 2024-10-03 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
BR112022017394A2 (pt) * 2020-03-23 2022-10-18 Lilly Co Eli Terapia de combinação com um inibidor de idh mutante
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
WO2022056453A1 (en) * 2020-09-14 2022-03-17 Totus Medicines Inc. Therapeutic conjugates
CN112353800B (zh) * 2020-11-10 2022-06-24 华熙生物科技股份有限公司 透明质酸或其盐和/或海藻糖的组合物及其在稳定麦角硫因中的用途
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2024249769A2 (en) * 2023-06-02 2024-12-05 Foghorn Therapeutics Inc. Combination therapy for treating hematological cancers
CN117838863B (zh) * 2023-12-26 2025-03-11 厦门大学 一种抑制d2hgdh的核酸分子、抑制剂及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
EP2406389B1 (en) 2009-03-13 2019-05-08 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
MX2011009989A (es) * 2009-03-23 2011-10-14 Ambit Biosciences Corp Metodos de tratamiento utilizando terapia de combinacion.
CA2793835C (en) 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
SG11201403878QA (en) 2012-01-06 2014-08-28 Agios Pharmaceuticals Inc Therapeutically active compounds and their methods of use
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
BR112015016282A2 (pt) * 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
NZ715738A (en) 2013-07-11 2021-06-25 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
TWI666208B (zh) 2013-08-02 2019-07-21 美商阿吉斯藥品有限公司 治療活性化合物及其使用方法（三）
CA2842635A1 (en) * 2014-01-20 2015-07-20 University Health Network Pre-cancerous cells and their identification in the prevention and treatment of cancer
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015127172A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2942072C (en) 2014-03-14 2022-07-26 Agios Pharmaceuticals, Inc. Pharmaceutical compositions and use of (s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-( 4-cyanopyridin-2-yl)-n-( 5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
RS62178B1 (sr) * 2014-03-14 2021-08-31 Les Laboratoires Servier Sas Farmaceutske kompozicije terapeutski aktivnih jedinjenja
WO2016053850A1 (en) * 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR102628370B1 (ko) 2015-02-04 2024-01-24 르 라보레또레 쎄르비에르 치료적 활성 화합물 및 이들의 사용 방법
US9751863B2 (en) 2015-08-05 2017-09-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
JP2019510746A (ja) 2019-04-18
CN109069410A (zh) 2018-12-21
IL261333B (en) 2022-03-01
AU2016393870B2 (en) 2023-01-19
MX391470B (es) 2025-03-21
IL261353A (en) 2018-10-31
EP3419594B1 (en) 2023-07-26
JP6856657B2 (ja) 2021-04-07
AU2016393869A1 (en) 2018-09-20
MA43640A (fr) 2018-11-28
US20200261434A1 (en) 2020-08-20
US20170246174A1 (en) 2017-08-31
AU2016393869B2 (en) 2022-10-27
IL261333A (en) 2018-10-31
EP3419593B1 (en) 2022-03-23
WO2017146794A1 (en) 2017-08-31
JP6930991B2 (ja) 2021-09-01
KR20180114202A (ko) 2018-10-17
JP2019513694A (ja) 2019-05-30
MX2018010261A (es) 2019-02-11
CA3015757A1 (en) 2017-08-31
MX2018010252A (es) 2019-01-31
US20190046512A1 (en) 2019-02-14
CN109069410B (zh) 2022-05-31
US10137130B2 (en) 2018-11-27
EP3419594A1 (en) 2019-01-02
EP3419593A1 (en) 2019-01-02
AU2016393870A1 (en) 2018-10-18
ES2912909T3 (es) 2022-05-30
JP2021102630A (ja) 2021-07-15
MX2021007790A (es) 2021-08-11
MX390396B (es) 2025-03-20
CA3015753A1 (en) 2017-08-31
WO2017146795A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
KR20180113540A (ko) 혈액암 및 고형 종양의 치료를 위한 idh2 저해제
EP3383400B1 (en) Methods of treatment of malignancies
US10695352B2 (en) Combination therapy for treating malignancies
US20210386749A1 (en) Combination therapy for treating malignancies
EP3493809B1 (en) Enasidenib for treatment of myelodysplastic syndrome
JP7093764B2 (ja) 骨髄異形成症候群の治療方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180823

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211201

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20220927

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240501

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250102

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D